Hematology-American Society of Hematology Education Program

Papers
(The TQCC of Hematology-American Society of Hematology Education Program is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Your chemo is no good here: management of high-risk MCL96
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?90
The varieties of therapeutic experience: navigating treatment options for patients with PNH65
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment61
Mastocytosis demystified50
Anticoagulation at the end of life: whether, when, and how to treat42
On the horizon: upcoming new agents for the management of ITP40
Labor and delivery: DIC, HELLP, preeclampsia40
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?32
Neurological manifestations of MGUS30
Challenges and opportunities in the long-term management of immune-mediated TTP29
Recognizing, defining, and managing CAR-T hematologic toxicities29
Inpatient recognition and management of HLH28
Bispecific antibody therapies28
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient26
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma26
New therapies in hemophilia: extend the half-life, mimic, or rebalance?25
Where do immunotherapies stand in management of acute leukemia in adults?25
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease24
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma24
Has PD-1 blockade changed the standard of care for cHL?24
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL24
New approaches to tackle cytopenic myelofibrosis23
Donor selection, graft engineering, and dosing oh my!23
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL23
Selecting initial therapy in CLL22
Fitness and frailty in myeloma22
Troubleshooting heparin resistance22
Optimizing outcomes in secondary AML22
Divergent paths: management of early relapsed follicular lymphoma22
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease21
BV and beyond: how to incorporate novel agents into PTCL management21
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia21
MGCS: where do we stand today?20
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?20
Incorporating novel agents into frontline treatment of Hodgkin lymphoma19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity19
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?19
How to assess hemostasis in patients with severe liver disease19
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?19
Hematology 2022—what is complete HLA match in 2022?19
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?19
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores19
How to manage hemostasis in patients with liver disease during interventions19
How to diagnose and manage antiphospholipid syndrome18
Consumptive coagulopathy in the ICU18
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation18
Management of TKI-resistant chronic phase CML17
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 20217
What's new in hereditary hemorrhagic telangiectasia?17
Atypical CML: diagnosis and treatment17
Demystifying autoimmune HIT: what it is, when to test, and how to treat17
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL17
Thrombosis questions from the inpatient wards16
Special considerations in GI bleeding in VWD patients16
Management of limited-stage Hodgkin lymphoma16
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies16
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma16
Management of marginal zone lymphomas16
Transplant in AML with measurable residual disease: proceed or defer?15
Approaches to management of HIT in complex scenarios, including cardiac surgery15
Pregnancy management for patients with bleeding disorders15
Organ function indications and potential improvements following curative therapy for sickle cell disease15
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment14
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment14
POEMS syndrome: diagnosis, treatments, and outcomes14
Alloimmunization and hyperhemolysis in sickle cell disease14
CNS prophylaxis in aggressive B-cell lymphoma14
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?14
Nontransplant treatment approaches for myeloid neoplasm with mutated TP5314
Management of autoimmune hemolytic anemia14
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing14
Pegylated interferon: the who, why, and how13
Cytoreduction for ET and PV: who, what, when, and how?13
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?13
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma13
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease13
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms12
What is the ideal approach—doublet, triplet, or quadruplet(s)?12
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?12
Thrombocytopenia in pregnancy12
What makes a pediatric or young adult patient an appropriate transplant candidate?12
Monoclonal gammopathy of renal significance from a hematologic perspective12
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax12
Treatment of VTE in the thrombocytopenic cancer patient12
Ph− ALL: immunotherapy in upfront treatment12
Future directions in transplantation for aplastic anemia12
Next-generation therapy for lower-risk MDS12
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS11
Should we use bisphosphonates to treat bone complications in sickle cell disease?11
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era11
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS11
Managing side effects: guidance for use of immunotherapies in multiple myeloma11
Managing pregnancy in patients with sickle cell disease from a transfusion perspective11
Clinical manifestations of telomere biology disorders in adults11
Novel therapies upon failure of HMA plus venetoclax11
What to know about rare B-cell malignancies in 202511
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?11
0.89136695861816